# A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

> **NCT04605588** · PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 7 (actual)

## Conditions studied

- SARS-CoV Infection
- Covid19

## Interventions

- **DRUG:** Nitazoxanide
- **DRUG:** Placebo Nitazoxanide
- **DRUG:** Ribavirin
- **DRUG:** Placebo Ribavirin
- **DRUG:** Hydroxychloroquine
- **DRUG:** Placebo Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04605588
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-02
- **Primary completion:** 2021-01-17
- **Final completion:** 2021-02-04
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Lack of participants willing to enroll
- **Last updated:** 2022-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605588, "A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04605588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*